Global Interventional Oncology Market 2017-2021
出 版 商：Technavio
出版日期：2017/03/13
頁 數：70頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 4,500 (Multi-User License)
USD 5,000 (Global-User License)
USD 4,500 (Multi-User License)
USD 5,000 (Global-User License)
About Interventional Oncology
Interventional oncology procedures involve the diagnosis and treatment of cancer and cancer-related problems by using minimally invasive (MI) procedures performed under image guidance. Interventional oncology uses X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to guide accessories and instruments, such as ablation electrodes, biopsy needles, guidewires, and intravascular catheters that allow the treatment of a tumor located in some part of the body. Interventional oncology treatments are regularly carried out by interventional radiologists with appropriate settings and facilities. Interventional oncology is used to treat primary or metastatic cancer, which includes liver cancer, lung cancer, kidney cancer, bone cancer, breast cancer, and prostate and pancreatic cancer.
Technavio’s analysts forecast the global interventional oncology market to grow at a CAGR of 11.17% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global interventional oncology market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of interventional oncology.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Interventional Oncology Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ BTG
‧ Boston Scientific
‧ Medtronic
‧ Merit Medical
‧ TERUMO CORPORATION
Other prominent vendors
‧ Accuray
‧ ALPINION MEDICAL SYSTEMS
‧ AngioDynamics
‧ AtriCure
‧ Baylis Medical
‧ BOVIE MEDICAL
‧ Brainlab
‧ BSD Medical Corporation
‧ C. R. Bard
‧ C2 Therapeutics
‧ CardioFocus
‧ Cook Medical
‧ Eckert and Ziegler BEBIG
‧ EDAP TMS
‧ Elekta
‧ Galil Medical
‧ HealthTronics
‧ INSIGHTEC
‧ MedWaves
‧ Mermaid Medical
‧ Microsulis Medical
‧ Monteris Medical
‧ NeuWave Medical
‧ Perseon
‧ Profound Medical
‧ Sirtex
‧ Smith & Nephew
‧ SonaCare Medical
‧ Varian Medical
Market driver
‧ Growing demand for MI procedures
‧ For a full, detailed list, view our report
Market challenge
‧ Risks associated with interventional oncology procedures
‧ For a full, detailed list, view our report
Market trend
‧ Growing integration of image-guided solutions with interventional oncology procedures
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Interventional oncology procedures involve the diagnosis and treatment of cancer and cancer-related problems by using minimally invasive (MI) procedures performed under image guidance. Interventional oncology uses X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to guide accessories and instruments, such as ablation electrodes, biopsy needles, guidewires, and intravascular catheters that allow the treatment of a tumor located in some part of the body. Interventional oncology treatments are regularly carried out by interventional radiologists with appropriate settings and facilities. Interventional oncology is used to treat primary or metastatic cancer, which includes liver cancer, lung cancer, kidney cancer, bone cancer, breast cancer, and prostate and pancreatic cancer.
Technavio’s analysts forecast the global interventional oncology market to grow at a CAGR of 11.17% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global interventional oncology market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of interventional oncology.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Interventional Oncology Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ BTG
‧ Boston Scientific
‧ Medtronic
‧ Merit Medical
‧ TERUMO CORPORATION
Other prominent vendors
‧ Accuray
‧ ALPINION MEDICAL SYSTEMS
‧ AngioDynamics
‧ AtriCure
‧ Baylis Medical
‧ BOVIE MEDICAL
‧ Brainlab
‧ BSD Medical Corporation
‧ C. R. Bard
‧ C2 Therapeutics
‧ CardioFocus
‧ Cook Medical
‧ Eckert and Ziegler BEBIG
‧ EDAP TMS
‧ Elekta
‧ Galil Medical
‧ HealthTronics
‧ INSIGHTEC
‧ MedWaves
‧ Mermaid Medical
‧ Microsulis Medical
‧ Monteris Medical
‧ NeuWave Medical
‧ Perseon
‧ Profound Medical
‧ Sirtex
‧ Smith & Nephew
‧ SonaCare Medical
‧ Varian Medical
Market driver
‧ Growing demand for MI procedures
‧ For a full, detailed list, view our report
Market challenge
‧ Risks associated with interventional oncology procedures
‧ For a full, detailed list, view our report
Market trend
‧ Growing integration of image-guided solutions with interventional oncology procedures
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
‧ Market overview
‧ Top-vendor offerings
PART 03: Market research methodology
‧ Research methodology
‧ Economic indicators
PART 04: Introduction
‧ Key market highlights
PART 05: Market landscape
‧ Market overview
‧ Five force analysis
PART 06: Market segmentation by procedure
‧ Ablation
‧ Global interventional oncology ablation market
‧ Embolization
‧ Global interventional oncology embolization market
PART 07: Geographical segmentation
‧ Interventional oncology market in Americas
‧ Interventional oncology market in EMEA
‧ Interventional oncology market in APAC
PART 08: Market drivers
‧ Growing cancer population
‧ Growing R&D activities
‧ Advances in technology
‧ Growing demand for MI procedures
PART 09: Impact of drivers
PART 10: Market challenges
‧ Risks associated with interventional oncology procedures
‧ High cost of interventional oncology procedures
‧ Presence of alternatives
‧ Limited skilled practitioners
PART 11: Impact of drivers and challenges
PART 12: Market trends
‧ Growing integration of image-guided solutions with interventional oncology procedures
‧ Increasing inorganic growth strategies by vendors
‧ Growing focus toward the adoption of MWA
‧ Growing adoption of SIRT and HIFU
‧ Competitive scenario
PART 13: Vendor landscape
‧ Key news
‧ Mergers and acquisitions
PART 14: Key vendor analysis
‧ Boston Scientific
‧ BTG
‧ Medtronic
‧ Merit Medical
‧ TERUMO CORPORATION
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits?
Exhibit 01: Product offerings
Exhibit 02: Key highlights of interventional oncology market
Exhibit 03: Snapshot of global interventional oncology market
Exhibit 04: Global interventional oncology market 2016-2021 ($ millions)
Exhibit 05: Interventional oncology market: Opportunity assessment
Exhibit 06: Five forces analysis
Exhibit 07: Global interventional oncology market segmentation by procedure
Exhibit 08: Global interventional oncology market segmentation by procedure 2016 and 2021
Exhibit 09: Global interventional oncology market segmentation by procedure 2016
Exhibit 10: Global interventional oncology market segmentation by procedure 2016: Lifecycle analysis
Exhibit 11: Global interventional oncology ablation market: Snapshot
Exhibit 12: Global interventional oncology ablation market 2016-2021 ($ millions)
Exhibit 13: Global interventional oncology embolization market: Snapshot
Exhibit 14: Global interventional oncology embolization market 2016-2021 ($ millions)
Exhibit 15: Global interventional oncology market segmentation by procedure 2016-2021 ($ millions)
Exhibit 16: Global interventional oncology market segmentation by procedure type 2016-2021 (%)
Exhibit 17: Global interventional oncology market segmentation by geography 2016 and 2021
Exhibit 18: Global interventional oncology market: Geographical presence
Exhibit 19: Global interventional oncology market segmentation by geography 2016
Exhibit 20: Global interventional oncology market segmentation by geography 2016: Lifecycle analysis
Exhibit 21: Interventional oncology market in Americas 2016-2021 ($ millions)
Exhibit 22: Market overview: Americas
Exhibit 23: Interventional oncology market in EMEA 2016-2021 ($ millions)
Exhibit 24: Market overview: EMEA
Exhibit 25: Interventional oncology market in APAC 2016-2021 ($ millions)
Exhibit 26: Market overview: APAC
Exhibit 27: Global interventional oncology market segmentation by geography 2016-2021 ($ millions)
Exhibit 28: Global interventional oncology market segmentation by geography 2016-2021
Exhibit 29: Impact of drivers
Exhibit 30: Complications associated with interventional oncology procedures
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Major M&A in global interventional oncology market
Exhibit 33: Comparison of MWA over RFA methods
Exhibit 34: Competitive structure analysis of global interventional oncology market 2016
Exhibit 35: Market share analysis of vendors in interventional oncology market 2016
Exhibit 36: Competitive landscape analysis of global interventional oncology market 2016
Exhibit 37: Strategic success factors of companies in global interventional oncology market
Exhibit 38: Boston Scientific: Key highlights
Exhibit 39: Boston Scientific: Strength assessment
Exhibit 40: Boston Scientific: Strategy assessment
Exhibit 41: Boston Scientific: Opportunity assessment
Exhibit 42: BTG: Key highlights
Exhibit 43: BTG: Strength assessment
Exhibit 44: BTG: Strategy assessment
Exhibit 45: BTG: Opportunity assessment
Exhibit 46: Medtronic: Key highlights
Exhibit 47: Medtronic: Strength assessment
Exhibit 48: Medtronic: Strategy assessment
Exhibit 49: Medtronic: Opportunity assessment
Exhibit 50: Merit Medical: Key highlights
Exhibit 51: Merit Medical: Strength assessment
Exhibit 52: Merit Medical: Strategy assessment
Exhibit 53: Merit Medical: Opportunity assessment
Exhibit 54: TERUMO CORPORATION: Key highlights
Exhibit 55: TERUMO CORPORATION: Strength assessment
Exhibit 56: TERUMO CORPORATION: Strategy assessment
Exhibit 57: TERUMO CORPORATION: Opportunity assessment
PART 01: Executive summary
PART 02: Scope of the report
‧ Market overview
‧ Top-vendor offerings
PART 03: Market research methodology
‧ Research methodology
‧ Economic indicators
PART 04: Introduction
‧ Key market highlights
PART 05: Market landscape
‧ Market overview
‧ Five force analysis
PART 06: Market segmentation by procedure
‧ Ablation
‧ Global interventional oncology ablation market
‧ Embolization
‧ Global interventional oncology embolization market
PART 07: Geographical segmentation
‧ Interventional oncology market in Americas
‧ Interventional oncology market in EMEA
‧ Interventional oncology market in APAC
PART 08: Market drivers
‧ Growing cancer population
‧ Growing R&D activities
‧ Advances in technology
‧ Growing demand for MI procedures
PART 09: Impact of drivers
PART 10: Market challenges
‧ Risks associated with interventional oncology procedures
‧ High cost of interventional oncology procedures
‧ Presence of alternatives
‧ Limited skilled practitioners
PART 11: Impact of drivers and challenges
PART 12: Market trends
‧ Growing integration of image-guided solutions with interventional oncology procedures
‧ Increasing inorganic growth strategies by vendors
‧ Growing focus toward the adoption of MWA
‧ Growing adoption of SIRT and HIFU
‧ Competitive scenario
PART 13: Vendor landscape
‧ Key news
‧ Mergers and acquisitions
PART 14: Key vendor analysis
‧ Boston Scientific
‧ BTG
‧ Medtronic
‧ Merit Medical
‧ TERUMO CORPORATION
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits?
Exhibit 01: Product offerings
Exhibit 02: Key highlights of interventional oncology market
Exhibit 03: Snapshot of global interventional oncology market
Exhibit 04: Global interventional oncology market 2016-2021 ($ millions)
Exhibit 05: Interventional oncology market: Opportunity assessment
Exhibit 06: Five forces analysis
Exhibit 07: Global interventional oncology market segmentation by procedure
Exhibit 08: Global interventional oncology market segmentation by procedure 2016 and 2021
Exhibit 09: Global interventional oncology market segmentation by procedure 2016
Exhibit 10: Global interventional oncology market segmentation by procedure 2016: Lifecycle analysis
Exhibit 11: Global interventional oncology ablation market: Snapshot
Exhibit 12: Global interventional oncology ablation market 2016-2021 ($ millions)
Exhibit 13: Global interventional oncology embolization market: Snapshot
Exhibit 14: Global interventional oncology embolization market 2016-2021 ($ millions)
Exhibit 15: Global interventional oncology market segmentation by procedure 2016-2021 ($ millions)
Exhibit 16: Global interventional oncology market segmentation by procedure type 2016-2021 (%)
Exhibit 17: Global interventional oncology market segmentation by geography 2016 and 2021
Exhibit 18: Global interventional oncology market: Geographical presence
Exhibit 19: Global interventional oncology market segmentation by geography 2016
Exhibit 20: Global interventional oncology market segmentation by geography 2016: Lifecycle analysis
Exhibit 21: Interventional oncology market in Americas 2016-2021 ($ millions)
Exhibit 22: Market overview: Americas
Exhibit 23: Interventional oncology market in EMEA 2016-2021 ($ millions)
Exhibit 24: Market overview: EMEA
Exhibit 25: Interventional oncology market in APAC 2016-2021 ($ millions)
Exhibit 26: Market overview: APAC
Exhibit 27: Global interventional oncology market segmentation by geography 2016-2021 ($ millions)
Exhibit 28: Global interventional oncology market segmentation by geography 2016-2021
Exhibit 29: Impact of drivers
Exhibit 30: Complications associated with interventional oncology procedures
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Major M&A in global interventional oncology market
Exhibit 33: Comparison of MWA over RFA methods
Exhibit 34: Competitive structure analysis of global interventional oncology market 2016
Exhibit 35: Market share analysis of vendors in interventional oncology market 2016
Exhibit 36: Competitive landscape analysis of global interventional oncology market 2016
Exhibit 37: Strategic success factors of companies in global interventional oncology market
Exhibit 38: Boston Scientific: Key highlights
Exhibit 39: Boston Scientific: Strength assessment
Exhibit 40: Boston Scientific: Strategy assessment
Exhibit 41: Boston Scientific: Opportunity assessment
Exhibit 42: BTG: Key highlights
Exhibit 43: BTG: Strength assessment
Exhibit 44: BTG: Strategy assessment
Exhibit 45: BTG: Opportunity assessment
Exhibit 46: Medtronic: Key highlights
Exhibit 47: Medtronic: Strength assessment
Exhibit 48: Medtronic: Strategy assessment
Exhibit 49: Medtronic: Opportunity assessment
Exhibit 50: Merit Medical: Key highlights
Exhibit 51: Merit Medical: Strength assessment
Exhibit 52: Merit Medical: Strategy assessment
Exhibit 53: Merit Medical: Opportunity assessment
Exhibit 54: TERUMO CORPORATION: Key highlights
Exhibit 55: TERUMO CORPORATION: Strength assessment
Exhibit 56: TERUMO CORPORATION: Strategy assessment
Exhibit 57: TERUMO CORPORATION: Opportunity assessment
